Juno is developing autologous cellular biologics as an answer to overcoming tumor evasion and potentially eradicating cancer cells. We believe the type of engineered T cell we put in the body matters, and we have developed the capability to manipulate and control the type of cells a patient receives, allowing us to develop potential “best-in-class” products that could deliver optimal therapeutic impact.